Literature DB >> 29735987

Sustainability and affordability of cancer drugs: a novel pricing model.

Carin A Uyl-de Groot1, Bob Löwenberg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29735987     DOI： 10.1038/s41571-018-0027-x

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Bone marrow niches in haematological malignancies.

Authors:  Simón Méndez-Ferrer; Dominique Bonnet; David P Steensma; Robert P Hasserjian; Irene M Ghobrial; John G Gribben; Michael Andreeff; Daniela S Krause
Journal:  Nat Rev Cancer       Date:  2020-02-28       Impact factor: 60.716

2.  Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.

Authors:  Bin Wu; Fei Ma
Journal:  Ther Adv Med Oncol       Date:  2020-05-05       Impact factor: 8.168

3.  The impact of early phase price agreements on prices of orphan drugs.

Authors:  Mark Nuijten; Philippe Van Wilder
Journal:  BMC Health Serv Res       Date:  2021-03-12       Impact factor: 2.655

4.  Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women.

Authors:  Eunae Jeong; Changjun Wang; Leslie Wilson; Lixian Zhong
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

5.  Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy.

Authors:  Ye Peng; Xiaohui Zeng; Liubao Peng; Qiao Liu; Lidan Yi; Xia Luo; Sini Li; Liting Wang; Shuxia Qin; Xiaomin Wan; Chongqing Tan
Journal:  Front Oncol       Date:  2021-11-09       Impact factor: 6.244

6.  Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.

Authors:  Joost J Enzing; Saskia Knies; Jop Engel; Maarten J IJzerman; Beate Sander; Rick Vreman; Bert Boer; Werner B F Brouwer
Journal:  Cost Eff Resour Alloc       Date:  2022-08-31

7.  Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.

Authors:  Xuezhi Hao; Aizong Shen; Bin Wu
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

8.  Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Authors:  Yanli Hou; Bin Wu
Journal:  Cancer Commun (Lond)       Date:  2020-11-07

Review 9.  Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.

Authors:  Peter Valent; Alberto Orfao; Stefan Kubicek; Philipp Staber; Torsten Haferlach; Michael Deininger; Karoline Kollmann; Thomas Lion; Irene Virgolini; Georg Winter; Oliver Hantschel; Lukas Kenner; Johannes Zuber; Florian Grebien; Richard Moriggl; Gregor Hoermann; Olivier Hermine; Michael Andreeff; Christoph Bock; Tariq Mughal; Stefan N Constantinescu; Robert Kralovics; Veronika Sexl; Radek Skoda; Giulio Superti-Furga; Ulrich Jäger
Journal:  Hemasphere       Date:  2021-02-17

10.  How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.

Authors:  Michael Schlander; Karla Hernandez-Villafuerte; Chih-Yuan Cheng; Jorge Mestre-Ferrandiz; Michael Baumann
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.